Press Releases for PDLI

Press Releases
PDL BioPharma Elects Barry Selick to Its Board of Directors
PDL BioPharma Announces Second Quarter 2009 Financial Results
PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009
PDL BioPharma Announces Record Date for October 1 Dividend Payment
PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
PDL BioPharma to Present at the 8th Annual JMP Securities Research Conference on May 18, 2009
PDL BioPharma Announces First Quarter 2009 Financial Results
Facet Biotech Reports First Quarter 2009 Financial Results
PDL BioPharma To Announce First Quarter 2009 Financial Results and Hold Conference Call May 7, 2009
PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer
AnalystChoice.Com Free CFA Opinion on TMX, SKM, PDLI and CRBC
PDL BioPharma Provides First Quarter 2009 Revenue Guidance of Approximately $60 Million
PDL BioPharma Announces Conversion Rate Adjustment for Its 2.75% Convertible Subordinated Notes Due August 16, 2023
PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00% Convertible Senior Notes Due February 15, 2012 - Mar 17 2009 8:05AM
PDL BioPharma Elects Frederick Frank and Jody Lindell to Its Board of Directors
PDL BioPharma to Present at the Cowen and Company 29th Annual Health Care Conference on March 18, 2009
PDL BioPharma Announces Fourth Quarter and Full Year 2008 Financial Results
PDL BioPharma to Host Fourth-Quarter and Full-Year 2008 Financial Results Conference Call on March 2, 2009
PDL BioPharma Receives Nasdaq Notice Related to Audit Committee Composition
PDL BioPharma Appoints Christopher L. Stone as Vice President, General Counsel and Secretary
PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00% Convertible Senior Notes Due February 15, 2012 - Jan 6 2009 6:36AM
Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
PDL BioPharma Appoints Christine Larson as VP and CFO
PDL BioPharma Announces Effectiveness of Form 10 Registration Statement of Facet Biotech
PDL BioPharma Resets Record Date for Spin-Off of Biotechnology Operations to December 5
David Parkinson, M.D. Elected to Facet Biotech's Board of Directors
PDL BioPharma Announces Record Date for Spin-Off of Biotechnology Operations
PDL BioPharma Reports Third Quarter 2008 Financial Results and Updates 2008 Guidance for Royalty Revenues
PDL BioPharma Appoints John P. McLaughlin to Become President and CEO Upon Completion of Spin-Off of Biotechnology Assets
PDL BioPharma Announces November 6 Webcast of Third Quarter 2008 Financial Results Conference Call
PDL BioPharma Elects Paul Sandman and John McLaughlin to Its Board of Directors
PDL BioPharma Names Faheem Hasnain President and Chief Executive Officer
PDL BioPharma Announces Participation at the UBS Global Life Sciences Conference and Webcast Presentation on September 25
BellwetherReport.Com Analyst Opinions on OTEX, PDLI, DISH and ALTR
PDL BioPharma Announces Investor Conference Call Today
Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma
PDL BioPharma Reports Second Quarter 2008 Financial Results
PDL BioPharma Appoints Gary A. Lyons to Its Board of Directors
PDL Announces Changes to Its Board of Directors
PDL BioPharma Reports First Quarter 2008 Financial Results - Jun 2 2008 1:28AM
Emerging Stock Report for Thursday, May 08, 2008: PUBM Blockbuster Potential! - May 27 2008 1:17AM
PDL Biopharma Announces Conversion Rate Adjustment for 2.00% Convertible Senior Notes Due February 15, 2012 - Jun 2 2008 1:28AM
New Analyst Reports for NOVA BIOSOURCE FUELS INC, ENDO PHARMACEUTICALS HOLDINGS INC, HYDROGENICS CORPORATION, and PDL BIOPHARMA INC - May 27 2008 1:16AM
PDL BioPharma Announces Data Presentations for Antibody Pipeline Products
PDL BioPharma Declares $500 Million Special Cash Dividend and Announces Plan to Separate Its Biotechnology Operations From Its Antibody Humanization Royalty Assets
Donald P. Beeman Is Appointed Chairman of the Board of Directors at LigoCyte Pharmaceuticals, Inc.
Protein Design Labs Sublicenses Rights to Develop Antibody-Drug Conjugates for Prostate Cancer to Genentech, Inc.